Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.
This article is from
The Cancer Letter
archive.
Vol. 30 No. 22 | May 28, 2004
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
NCI Awards $10 Million To States for Cervix Screening
September 27, 1974
TCL Archive
Katterhagen, Nelson Reelected ACCC Leaders
February 4, 1977
TCL Archive
Molecular target Drug Discovery Grants; Unanimously Approved
July 2, 1999
TCL Archive
Oral Combination Provides Alternative To IV Chemo For Multiple Myeloma
November 29, 2002
TCL Archive
AACR Calls For Clear Statement; Says Report Was “Premature”
February 14, 1997
TCL Archive
Chemo Can Harm Liver, Affect Surgical Outcomes
May 26, 2006